Atnaujinkite slapukų nuostatas

El. knyga: Essentials of Lung Transplantation

, ,
  • Formatas: 206 pages
  • Išleidimo metai: 26-Mar-2025
  • Leidėjas: CRC Press
  • Kalba: eng
  • ISBN-13: 9781040320518
Kitos knygos pagal šią temą:
Essentials of Lung TransplantationDidesnis paveikslėlis
  • Formatas: 206 pages
  • Išleidimo metai: 26-Mar-2025
  • Leidėjas: CRC Press
  • Kalba: eng
  • ISBN-13: 9781040320518
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

Lung transplantation (LTx) is a life-saving treatment for people with severe end-stage lung disease. This concise, well-illustrated practical handbook provides a comprehensive overview of pre-, peri-, and post-transplant care addressing the complexity of lung transplantation, general follow-up, and common post-transplant complications. Simple, to-the-point short topics will answer potential questions by LTx trainees, fellows, and consultants; educating healthcare professionals involved in the care of LTx patients explaining the post-transplant journey along with examples of real-life cases.

Key Features

  • Presents answers to common clinical questions during the post-transplant journey of a lung transplant recipient
  • Shares practical/pragmatic approaches to diagnostic and management issues seen in the lung transplant population for clinicians from both within and external to transplant centres internationally, to gain practical experience
  • Summarises the clinical aspects of LTx, with easy-to-navigate short text blocks, bullet points, and illustrations


Lung transplantation (LTx) is a life-saving treatment for people with very severe end-stage lung diseases. It educates healthcare professionals involved in the care of LTx patients by explaining the general post-transplant journey, addressing typical post-transplant complications, and providing examples of real-life cases.

1. Lung transplantation. 1.1 Lung transplantation: where are we today? 1.2 Ethical considerations regarding lung transplantation.
2. Pre-transplant. 2.1 Indications for lung transplantation. 2.2 How to select a good recipient? 2.3 A patient on the waiting list: how to manage and when to transplant. 2.4 How are organs allocated? 2.5 How to select a good donor?
3. Peri-transplant. 3.1 Type of lung transplantation. 3.2 Type of procedure. 3.3 ECMO, cardiopulmonary bypass and off-pump. 3.4 What is ischaemia time? 3.5 Should we use ex vivo lung perfusion? 3.6 To induce or not?
4. Post-transplant medication and follow-up. 4.1 Maintenance immunosuppression. 4.2 Prophylaxis. 4.3 What to expect after lung transplantation?. 4.4 General follow-up post-transplant. 4.5 Surgery in lung transplant patients. 4.6 Pregnancy and lung transplantation. 4.7 Medication interactions.
5. General post-operative complications and primary graft dysfunction . 5.1Pleural complications. 5.2 Ischaemic airway complications and fistulas. 5.3 Other post-operative complications. 5.4 Primary graft dysfunction (PGD).
6. Post-transplant complications: rejection. 6.1 Introduction acute and chronic rejection. 6.2 Hyperacute rejection: does it still exist?.6.3 Acute cellular rejection (ACR). 6.4 Donor specific antibodies (DSA): what and how to interpret?6.5 Antibody-mediated rejection (AMR). 6.6 Chronic rejection: chronic lung allograft dysfunction (CLAD). 6.7 Bronchiolitis obliterans syndrome (BOS). 6.8 Restrictive allograft syndrome (RAS). 6.9 Biomarkers and future therapies.
7. Other common post-transplant complications. 7.1 Infections. 7.2 Malignancies. 7.3 Kidney dysfunction. 7.4Metabolic complications and cardiovascular disease. 7.5 Reflux and other gastrointestinal issues: why it matters. 7.6 PRES: posterior reversible encephalopathy syndrome.
8. Clinical cases. 1.3Clinical case: early post-operative evolution. 1.4 Clinical case: ACR, infection and CLAD . 1.5Clinical case: CMV infection. 1.6 Clinical case: PTLD

Dr Saskia Bos, MD, PhD, worked from 2020 to 2024 as a clinical researcher at Newcastle University and as a transplant physician at the Institute of Transplantation of the Freeman Hospital, Newcastle upon Tyne, UK. She then moved back to Belgium, where she now works as a transplant pulmonologist in the Leuven Lung Transplant Program and is Adjunct Head of Clinic of the Department of Respiratory Diseases at the University Hospitals Leuven. She has a specific interest in chronic lung allograft dysfunction, pulmonary graft-versus-host disease after haematopoietic stem cell transplantation and infectious diseases in solid organ transplants. She is active in several European and International Societies (European Respiratory Society, European Society for Organ Transplantation, International Society for Heart and Lung Transplantation, and European Society of Clinical Microbiology and Infectious Diseases).

Robin Vos, MD, PhD, is Medical Director of the Leuven Lung Transplant Program, Deputy Head of Clinic of the Department of Respiratory Diseases at the University Hospitals Leuven and Associate Professor of Medicine at KU Leuven, Belgium. He is a Senior Clinical Research Fellow of the Research Foundation - Flanders and his clinical and translational research focuses on the pathophysiology and treatment of chronic lung allograft dysfunction and pulmonary chronic graft-versus-host-disease. He is a Fellow of the European Respiratory Society (FERS) and active in several European and International Societies (Eurotransplant, European Respiratory Society, European Society for Organ Transplantation, and International Society for Heart and Lung Transplantation).

Andrew J. Fisher, FRCP, PhD, is Professor of Respiratory Transplant Medicine at Newcastle University and a transplant pulmonologist at the Institute of Transplantation at Freeman Hospital, Newcastle upon Tyne, UK with almost 30 years of experience. He is Co-Director of the NIHR Blood and Transplant Research Unit in Organ Donation and Transplantation and leads a team of scientists and clinicians who are working on better understanding how outcomes after lung transplantation can be improved. He has led education initiatives on lung transplantation for the European Respiratory Society, British Thoracic Society and International Society for Heart and Lung Transplantation (ISHLT) and is a Past President of ISHLT.
Daugiau apie elektronines knygas Daugiau apie elektronines knygas
Pastovi nuoroda: https://www.kriso.lt/db/97810403205182e.html